Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination

Figures & data

Table 2 Benefits of combination therapy in hypertension

Better adherence to therapy and simplification of the therapeutic regimen Better blood pressure control than monotherapy Avoidance of dose-dependent adverse effects seen with higher doses of single agents Attenuation of the adverse effects of some agents when used alone Complementary/synergistic vasculoprotective or pleiotropic effects.

Table 1 Guidelines for initial combination therapy

Committee	BP levels requiring initial combination therapy
JNC-7^Citation35	Stage 2 (≥160/100 mmHg) SBP > 20 mmHg or DBP > 10 mmHg above the goal
NKF^Citation36	SBP > 20 mmHg above the goal according to the stage of CKD and CVD risk
ADA^Citation37	BP > 130/80 mmHg and Type 2 diabetes
ESH^Citation10	High-risk patients according to total CVD risk

Abbreviations: JNC-7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; NKF, National Kidney Foundation; ADA, American Diabetes Association; ESH, European Society of Hypertension; CKD, chronic kidney disease; CVD, cardiovascular disease; BP, blood pressure.

Table 3 Proportion of patients achieving target blood pressure (<140/90 mmHg or <130/80 mmHg in patients with diabetes mellitus) by week eight/last observation carried forward according to subgroup and treatment regimen

Goal BP achieved (%)	Age		Race		Diabetes status		BMI
	<65	≥65	Black	Nonblack	DM	non-DM	<30 kg/m^2	≥30 kg/m^2
Placebo	10.9	0	4.4	10.4	8.7	8.8	12.0	7.3
Amlodipine 10 mg	32.8	31.1	43.6	29.0	8.7	36.4	30.3	34.4
Olmesartan 40 mg	41.1	16.1	15.9	44.0	9.5	40.3	47.9	30.0
Amlodipine–olmesartan (10/40 mg)	56.3	21.2	38.2	52.0	12.5	55.5	53.3	46.0

Abbreviations: DM, diabetes mellitus; BMI, body mass index; BP, blood pressure.

ChobanianAVThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA20032892560257212748199

 PubMed Web of Science ®Google Scholar

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney diseaseAm J Kidney Dis2004431113

 PubMed Web of Science ®Google Scholar

Summary of Revisions for the 2007 Clinical Practice RecommendationsDiabetes Care200730S3

 PubMed Web of Science ®Google Scholar

Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension*J Hypertens200321

 Google Scholar